230 results about "Infection induced" patented technology

This invention provides a treatment regimen that is effective in inhibiting chemotherapy-induced apoptosis and promoting cell survival. The invention also relates to a treatment regimen that confers resistance to caspase activation, thereby inhibiting caspase-mediated, proteolytic cleavage of functional cellular enzymes. Specifically, subjects undergoing chemotherapy are first exposed to a pretreatment regimen. Under this regimen, a GLP-2 receptor activator, such as h[GLY2]-GLP2, is administered each day for a predetermined beneficial period, e.g., three consecutive days. Approximately about 1 week following pretreatment, the subjects are exposed to an appropriate chemotherapy treatment regimen. Pretreatment with a GLP-2 receptor activator followed by administration of chemotherapeutic agents improves cell survival, reduces bacteremia, attenuates epithelial injury, and inhibits cellular apoptosis. Moreover, it does not impair the effectiveness of chemotherapy nor result in weight loss. The anti-apoptotic effects of GLP-2 may be useful in the reduction of cytoxicity and bacterial infection induced by chemotherapeutic agents.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of novel coronaviruses. Specifically, the present inventionrelates to an anti-novel coronavirus monoclonal antibody, and a composition (e.g., a diagnostic agent and a therapeutic agent) comprising the antibody. Furthermore, the invention also relates to an application of the antibody. The antibody provided by the invention can be applied to diagnosis, prevention and / or treatment of infection of the novel coronavirus and / or diseases (e.g., novel coronavirus pneumonia) caused by the infection.

The invention provides methods for determining the propensity to develop, or the presence of, one or more infection-induced illness(es). The invention further provides methods of treating an infection (e.g., bacterial infection), methods of diagnosing an infection-induced illness in a subject, and methods of predicting the future severity of one or more infection-induced illness(es). Also provided are kits for determining the likelihood or propensity of a subject to develop one or more infection-induced illness(es) and kits for diagnosing one or more infection-induced illness(es) in a subject and identifying a subject as having an increased risk of later developing one or more severe infection-induced illness(es).

Non-replicating vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described for in vivo immunization. The nucleotide sequence encloding the RSV F protein may lack a sequence encoding the homologous signal peptide but possessing a heterologous signal peptide enhancing RSV F protein expression. Such non-replicating vectors, including plasmids, also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such non-replicating vectors may be used to immunize a host against disease caused by infection with RSV, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purpose. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.

The present invention discloses a recombinant baculovirus strain rBac / PCV2Cap (microorganism preservation number: CGMCC NO.2083) efficiently expressing Porcine circovirus type 2 Cap protein and applications thereof. The recombinant baculovirus strain rBac / PCV2Cap constructed by the present invention can efficiently express recombinant PCV2-Cap protein in insect cells, and the expressed recombinant Cap protein, which has good immunocompetence and antigenicity, can serve as a subunit vaccine used to prevent the related plague caused by Porcine circovirus type 2 infection as well as a detecting and diagnostic antigen for Porcine circovirus type 2 serum antibody.

The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5′-truncated or 3′-truncated 76 kDa protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 76 kDa protein gene in the host. Modifications are possible within the scope of this invention.

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and / or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

Certain human genes have been found to be induced or repressed in host cells infected with HCMV. A large set of such genes has been identified. These have diagnostic use in determining the extent of tissue damage caused by the infection as well as in determining the stage of disease progression of the HCMV infection. Such genes are likely those involved in mediating the pathology of the infected tissues. Thus by identifying agents which are able to reverse the induction or repression of such genes, one can find candidate therapeutic agents for use in treating and or preventing HCMV-caused disease pathologies.

The invention provides a Li nation medicament nakedflower beautyberry leaf extract with bacteriostatic, anti-inflammatory and hemostasis effects and a preparation method thereof, and a medicinal composition comprising the active extract. The extract and the medicinal composition comprising the extract are used for treating inflammation caused by bacterial infection, acute infectivity hepatitis, and bleeding of orifices such as the respiratory tract and the digestive tract, and do not have toxic or side effect. The extract can be prepared into any oral preparation for treating the inflammation caused by bacterial infection, the acute infectivity hepatitis, and the bleeding of orifices such as womb, vagina, the respiratory tract and the digestive tract.

The invention relates to a compound vaccine composition for preventing and treating human papillomavirus infection, a compound vaccine vaginal spray and uses thereof, and belongs to the field of vaccine preparations with targeted treatment indications. The product of the present invention can prevent cervical cancer and treat HPV infection; it is suitable for married women of any age; it can prevent and treat chronic cervicitis and cervical epithelial dysplasia caused by sexually transmitted HPV infection, including CIN I, II, III Degree, inhibit HPV reproduction, prevent cervical cancer.

The invention relates to an antibody for identification of epitopes on influenza virus hemagglutinin protein HA1 structural domains, a cell strain generating the antibody and the use of the antibody and the cell strain. The antibody is can cross the HA subtype for specific binding of the hemagglutinin (HA) protein HA1 structural domains of H1 subtype (including seasonal H1N1 and new H1N1) and H5 subtype influenza virus. Therefore, the invention also relates vaccines or pharmaceutical compositions which comprise the antibody and are used for prevention and / or treatment of H1 subtype and H5 subtype influenza virus infection and / or diseases (such as the flu) induced by the H1 subtype and H5 subtype influenza virus.

The present invention relates to mhp3 nucleic acids and proteins encoded by the foregoing. The present invention further relates to novel apoprotein antigens encoded by mhp3 for use in vaccines to prevent and treat diseases caused by infection with Mycoplasma hyopneumoniae. The invention further relates to methods for the recombinant production of such antigens.

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from the Chalmydia gene 60kCRMP gene including truncated forms of the gene. The invention further provides recombinant 60kCRMP protein useful for protecting against disease caused by infection with Chlamydia.

The invention relates to the pharmacy field, concretely relates to a use of a series of pentacyclic triterpene compounds as enterovirus EV71 inhibitors, and especially relates to an application in the preparation of medicines for preventing and treating EV71 infection induced hand-foot-and-mouth diseases and complications thereof, such as synanche, myocarditis, pulmonary edema, encephalitis, herpes, septicemia, hypertension, hyperglycemia, cognitive function disorder, poliomyelitis-like paralysis and many nerve system associated diseases. The invention also discloses medicinal compositions of the series of the pentacyclic triterpene compounds as enterovirus EV71 inhibitors.

The invention relates to a lignin compound that could prevent yellow staphylococcal bacteria and B type hemolytic streptococcus, and the medicine combination of the compound. The invention of lignin Morgan dandehon herb acid A and Rufescidride has obviously effect restraining yellow staphylococcal and B type hemolytic streptococcus. It is also respected to prevent the diseases caused by them, like boil, blain, toxicity epidermis necrolysis, pneumonia, etc.

Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum, and Salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum or Salmonella pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the Salmonella bacteria. The present invention also provides important insights into prevention and control strategies against Salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of Salmonella infection in poultry.

Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Pullorum without affecting beneficial bacteria. Disclosed are also compositions, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella Enteritidis, Salmonella Typhimurium, Salmonella Gallinarum or Salmonella Pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the salmonella bacteria.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of SARS-Cov-2. In particular, the present invention provides monoclonal antibodies that can recognize SARS-Cov-2 mutants, as well as compositions (e.g., diagnostic agents and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosis, prevention and / or treatment of SARS-Cov-2 infection and / or diseases caused by the infection (e.g., COVID-19).

The present invention provides compositions and methods for the prevention and treatment of an infectious disease caused by infection with HIV and for stimulating an immune response in a subject. In particular, the present invention provides Apicomlexa-related proteins (ARPs) that have immune stimulatory activity and thus have uses in the treatment and prevention of an infectious disease caused by infection with HIV and in immune modulation. Compositions comprising an ARP are provided. Methods of use of an ARP for the prevention and / or treatment of an infectious disease caused with infection with HIV, and for eliciting an immune response in a subject, are also provided.

The invention discloses a lung-heat clearing mixture for treating various pneumonia, upper respiratory diseases, bronchitis, tonsillitis and other disease symptoms caused by bacterial infection and viral infection and a preparation method thereof. The lung-heat clearing mixture consists of eleven traditional Chinese medicines of scutellaria, isatidis root, honeysuckle, fructus forsythiae, herba taching, dandelion, rhizoma paridis, pericarpium citri reticulatae, balloonflower root, armeniaca amara and folia eriobotryae. The medicine materials are decocted for several times; volatile oil is collected; medicine liquid is mixed, is condensed, is added with edible essence and the like, is adjusted to certain amount and is evenly stirred, subpackaged and sterilized to obtain a finished product. The lung-heat clearing mixture emphasizes on coldness and coolness, aims at pathogenesis, clears away heat and toxic materials, mainly eliminates the pathogenic factor to effect a permanent cure, uses a product for dissipating phlegm and relieving cough, reaches lung vessels and disperses and descends lung qi to alleviate the symptoms; and the medicines have clear master-slave, mutual correspondence, precise compatibility and proper stipulation, so as to have the effects of clearing away the lung-heat, reliving heat, detoxicating, relieving sore throat, dissipating phlegm and relieving cough; and clinical experiments show that the total effective rate reaches over 90 percent.

The invention provides a novel vaccine with the same immunoefficiency as the prior infectious laryngotracheitis virus (ILTV) attenuated vaccine and capable of overcoming dormant infection induced by the attenuated vaccine. The invention provides the nucleotide sequence and amino acid sequence of an ILTV glycoprotein D (gD) and a preparation method, as well as a recombinant vaccine containing a viral vector (fowlpox virus vector) and ILTV gD. The fowlpox virus is obtained by homologous arm recombination of ILTV gD. The invention also provides the preparation method of the recombinant vaccine. The invention clones gD gene of ILTV Henan isolate, and performs animal experiments of the immunoprotection of the recombinant fowlpox virus. The novel vaccine has the same immunoefficiency as the prior ILTV attenuated vaccine and is capable of overcoming the shortcomings of the attenuated vaccine. The invention is convenient for large-scale production, and provides a foundation for prevention and elimination of infectious laryngotracheitis (ILT).

The invention discloses an application of a benzo Alpha-pyrone compound as a Gamma-type human herpes virus-resistant medicine. According to the invention, the compound resistant to Gamma-type human herpes virus infection is higher in activity as compared with a novobiocin which is a marketed medicine, and is less in toxicity based on a cytoxicity test. The compound can be used for curing or preventing related diseases caused by KSHV infection.

The invention relates to an electronic recording umbilical cord cutter which comprises a push-cut rod, a mother clamp, a baby clamp and a clamp holder, wherein a blade is installed at one end of the push-cut rod, the other end is connected with an electronic display with a switching key and a signal key, a pulling sheet is fixed on one surface and matched with the baby clamp, one end of the clampholder is connected with the mother clamp and the baby clamp, an inner wall sliding slot at the other end is matched with the push-cut rod, and the signal key on the electronic display is also matched with the clamp holder. The whole operating process is clearly seen from a large opening, an umbilical cord is firstly clamped tightly by the two clamps and then cut by pushing the push-cut rod by hand, the electronic recording umbilical cord cutter not only is easy to cut, but also has good cutting effect, saves labor and can avoid a phenomenon of blood sputtering, thereby guaranteeing the physical and mental health of medical personnel and avoiding the infection induced by a long umbilical head. Because the electronic display is installed on the cutter, the natal time information of newborns can be recorded, displayed and stored, and the cutter also can be used as a souvenir and permanently saved after washing and disinfection processing, thereby increasing the function and the reserve value thereof.

Through suppression of the multiplication of pathogenic bacteria and inactivation of bacterial self-induced factors, the balance of intestinal flora is improved to thereby promote regulation of animal intestinal functions and enable prevention / treatment of infection induced by such pathogenic bacteria. Accordingly, a pharmaceutical containing Bacillus thuringiensis is administered to animals, and animals are caused to ingest a food or feed containing Bacillus thuringiensis.

Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

The invention discloses a skin antimicrobial gel recipe and a preparation method thereof. The gel comprises the raw materials of chitosan-iodine, glacial acetic acid, polysorbate-20, glycerin, potassium iodate, chitosan and purified water. The preparation method comprises the following steps of: (1) weighing; (2) adding the glacial acetic acid, the polysorbate-20, the glycerin and the purified water into the chitosan-iodine, mixing uniformly and dissolving completely; (3) dissolving the potassium iodate with the purified water, and adding the dissolved potassium iodate into the mixture to be stirred uniformly; (4) adding the chitosan to stir and dissolve; and (5) adding the purified water to 100% finally, slowly stirring to form the gel, standing and degassing to obtain a skin antimicrobial gel finished product. The skin antimicrobial gel has the advantages of no toxicity, no stimulus, good stability and no tolerance; and the skin antimicrobial gel is suitable for treating and preventing skin and subcutaneous infection and promoting wound healing, such as primary skin infection of impetigo vulgaris, furuncle and the like, secondary skin infection of eczema concurrent infection, trauma concurrent infection and the like as well as tinea manus and pedis, tinea corporis and tinea cruis which are caused by fungal infection.

The human-derived anti-Hepatitis A virus genetically engineered antibody produced by CHO cells includes two strains of human-derived anti-Hepatitis A virus neutralizing genetically engineered antibody CHO (Chinese hamster ovary cell) production cell line and the production of human-derived anti-Hepatitis A virus neutralizing for prevention and treatment Genetically engineered antibody preparations. Its product features are fully human antibodies IgG1λ and IgG1κ derived from phage human antibody library screening and human IgG Fc gene recombination in Chinese hamster ovary (CHO) cells stably expressing cells, named ChHAIgG16 and ChHAIgG78 respectively. The molecular weight is about 150kd. The cocktail-type antibody preparation composed of ChHAIgG16 and ChHAIgG78 mixed at a ratio of 3:1 is named HAMaxTMM. Utilizing its functional characteristics of highly neutralizing hepatitis A virus infection and the molecular structure characteristics of whole antibodies similar to natural antibody molecules, it is expected to replace blood product gamma globulin in clinical practice for the prevention and treatment of hepatitis A caused by hepatitis A virus infection .

The invention discloses natural anti-inflammatory polypeptide cecropin-TY1 extracted from salivary glands of Tabancus yao. The natural anti-inflammatory polypeptide cecropin-TY1 comprises 39 amino acids, the carbon tail end is amidated, the molecular weight is 3970.22 Dalton, the isoelectric point is 11.17, the amino acid sequence is SEQ ID: 1, and all the amino acids are L-type. The natural anti-inflammatory polypeptide cecropin-TY1 has the characteristics of small molecular weight, remarkable anti-inflammatory effect and low cytotoxicity, has wide application prospects in anti-inflammatory drugs, drugs for treating septicopyemia and endotoxin shock caused by bacterial infection, veterinary drugs, animal feed and cosmetics and is particularly applied to inhibiting lipopolysaccharide induced macrophages from generating nitric oxide, inhibiting lipopolysaccharide induced macrophages from generating inflammatory cell factors, inhibiting a lipopolysaccharide induced inflammation signal path as well as neutralizeing the endotoxin.

The invention discloses an alpha-mangostin derivative in preparation of an anti-cerebral palsy medicine and an anti-cerebral palsy medicine composition. The effective ingredient of the anti-cerebral palsy medicine composition is the alpha-mangostin derivative. By applying the alpha-mangostin derivative in the preparation of the anti-cerebral palsy medicine, the reduced learning and memory abilityof the brain caused by hypoxia ischemia and infection can be restored, the gait balance ability can be improved, and the damage of neuronal organelles can be relieved.